Search­ing for a few great drugs, Bridge­Bio bags $135M to back a fresh slate of R&D bets

Bridge­Bio is all about shots on goal.

The last time I wrote a sto­ry about the com­pa­ny in April, CEO Neil Ku­mar had just es­tab­lished his 9th sub­sidiary op­er­a­tion to ex­plore a small mol­e­cule ther­a­py for transthyretin (TTR) amy­loi­do­sis. And now it’s lined up $135 mil­lion — more than it’s ever raised be­fore — to es­tab­lish up to 10 more of these R&D ef­forts.

Sig­nif­i­cant­ly, KKR came back in to co-lead the round, joined by new in­vestor Viking Glob­al In­vestors. Ex­ist­ing in­vestor Per­cep­tive Ad­vi­sors came back in, along­side a slate of new in­vestors: AIG, Ais­ling Cap­i­tal, Cor­morant Cap­i­tal and Janus Funds.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER